NAMCP Medical Directors Institute Home
AAMCN
Managed Care Nurses Association Home
Continuing Education Home

 

Chronic Illness
CME Online

The newest CME presentations are at the top of this page.
Those nearing expiration are nearer the bottom of the page.

Business/Practice Management Preventive Health & Lifestyle Medicine Chronic Illness
Behavioral Health Oncology Genomics, Biotech & Emerging Medical Technologies


AutoImmune    Cardiovascular     Diabetes     Infectious Disease     Musculoskeltal/Rheumatology     Neurological     Pain Management     Pulmonary
 

AutoImmune
 

A 4 Part Series:  New Horizons in the Treatment and Management of Atopic Dermatitis (AD): How Novel Therapies are Changing the Treatment Paradigm
Description:
  Description: Atopic dermatitis is a common chronic inflammatory skin disease characterized by persistent itching that can severely affect quality of life. This condition evolves from a combination of skin barrier defects and immune-mediated responses involving activated T-helper cells and related cytokines. Our improved understanding of the pathophysiology underlying atopic dermatitis is resulting in the development of targeted therapies for children and adult patients with this disease. There are approximately 17.8 million people with moderate to severe eczema or atopic dermatitis in the United States. Current treatments adequately care for patients with atopic dermatitis, but have shown problems with sustained efficacy in patients with severe eczema or atopic dermatitis. Fortunately for patients with this disease, several new treatments have recently undergone late stage clinical trials that have shown improved efficacy and safety, offering patients the potential for improved outcomes and quality of life. This activity will focus on the latest clinical data on these evolving options, how clinicians can potentially integrate them into the treatment paradigm, options for patients who have received prior therapies, and information on the mechanisms of action of these agents.

Current atopic dermatitis treatments attempt to reduce inflammation and itchiness to maintain the protective integrity of the skin. These treatments have shown the ability to managed the disease in the short term, but have had troubles with long term efficacy. A recent update to the American Academy of Dermatology guidelines of care for the management of adult and pediatric patients recommends a proactive approach for long-term disease management versus episodic management of flares with an emphasis on clinical assessment of disease severity. Several treatments, including novel monoclonal antibodies, have shown the ability in late stage clinical trials to block various proteins that mediate inflammation and immune responses, potentially arresting development and progression of the disease at various pathogenic steps. These new options have shown improved efficacy and safety in atopic dermatitis, and medical directors, practicing physicians, nurses and other healthcare professionals must be educated on these options and how they might affect the current treatment paradigm.
This multi-part program on new horizons and novel therapies in atopic dermatitis will provide medical directors, practicing physicians and nurses with the latest clinical data on novel treatments that have recently completed late stage clinical trials. Clinicians need to be updated on these treatment options and the potential integration of newer agents, in order to optimize the care of their patients, especially in the area of inadequately controlled moderate-to-severe atopic dermatitis patients.
Physician, Nursing and CMCN credits apply.  Each session has its own specific valid dates
 

New Approaches to Atopic Dermatitis
Atopic dermatitis (AD) is a common chronic inflammatory skin disease characterized by persistent itching that can severely affect quality of life. This condition evolves from a combination of skin barrier defects and immune-mediated responses involving activated T-helper cells and related cytokines. Our improved understanding of the pathophysiology underlying atopic dermatitis is resulting in the development of targeted therapies for children and adult patients with this disease. There are approximately 17.8 million people with moderate to severe eczema or atopic dermatitis in the United States. This session will address the novel and emerging therapies available for AD.

Physician, Nursing and CMCN credits valid to April 30, 2019
 

Extending the Translational Revolution to Atopic Dermatitis and Other Inflammatory Skin Diseases
Atopic dermatitis is a common chronic inflammatory skin disease characterized by persistent itching that can severely affect quality of life. This condition evolves from a combination of skin barrier defects and immune-mediated responses involving activated T-helper cells and related cytokines. Our improved understanding of the pathophysiology underlying atopic dermatitis is resulting in the development of targeted therapies for children and adult patients with this disease. There are approximately 17.8 million people with moderate to severe eczema or atopic dermatitis in the United States. This session will address how to manage patients not controlled by standard therapy, the challenges, tailored treatment plans and continued patient assessments.

Physician, Nursing and CMCN credits valid to April 30, 2019
 

Recent Advances in Understanding the Pathogenesis of Atopic Dermatitis
Atopic dermatitis is a common chronic inflammatory skin disease characterized by persistent itching that can severely affect quality of life. This condition evolves from a combination of skin barrier defects and immune-mediated responses involving activated T-helper cells and related cytokines. Our improved understanding of the pathophysiology underlying atopic dermatitis is resulting in the development of targeted therapies for children and adult patients with this disease. There are approximately 17.8 million people with moderate to severe eczema or atopic dermatitis in the United States. This session will address the role of emerging therapies and their pathophysiologic mechanisms that block IL-4/IL-13 pathways.
Physician, Nursing and CMCN credits valid to April 30, 2019
 

New Horizons in the Treatment and Management of Atopic Dermatitis (AD): What Managed Care Needs to know about Novel Therapies in the Evolving Management of Atopic Dermatitis
Atopic dermatitis is a common chronic inflammatory skin disease characterized by persistent itching that can severely affect quality of life. This condition evolves from a combination of skin barrier defects and immune-mediated responses involving activated T-helper cells and related cytokines. Our improved understanding of the pathophysiology underlying atopic dermatitis is resulting in the development of targeted therapies for children and adult patients with this disease. There are approximately 17.8 million people with moderate to severe eczema or atopic dermatitis in the United States. This session will provide attendees with perspectives and strategies used to manage an AD population by managed care organizations.  Physician, Nursing and CMCN credits valid to April 30, 2019
 

Clinical Advances in Atopic Dermatitis: Novel Therapies for Improved Patient Outcomes
Atopic dermatitis (AD) is a common chronic inflammatory skin disease characterized by persistent itching that can severely affect quality of life. This condition evolves from a combination of skin barrier defects and immune-mediated responses involving activated T-helper cells and related cytokines. Current atopic dermatitis treatments attempt to reduce inflammation and itchiness to maintain the protective integrity of the skin and have shown the ability to manage the disease in the short term, but have had troubles with long term efficacy. Fortunately several new treatments, including novel monoclonal antibodies or targeted therapies, have shown improved efficacy and safety, offering patients the potential for improved outcomes and quality of life.
Physician, Nursing and CMCN credits valid to January 31, 2018
 
Shaping the Future of Psoriasis through Advanced Therapeutic Strategies
Psoriasis is a complex, chronic, immune-mediated inflammatory disease presenting with periodic flare-up of sharply defined red patches, covered by a silvery, flaky surface and affects approximately 7 million people in the US. The disease most commonly appears on the skin of the scalp, elbow, knees, and lumboscaral areas of the body. Many patients are not receiving the appropriate treatment discussed in the current guidelines and standards of care. Psoriasis is a very expensive disease for the American health system and is difficult to manage thus the goal should be patient-centered treatment that reduces cost, disease burden, improves quality-of-life, and addresses the risks of systemic complications and comorbid conditions. There are several treatment options to include topical treatments, from over the counter (OTC) to prescription, phototherapy, laser therapy and traditional systemic medication. Emerging options such as Biologics can be very effective but proper management must be done in order to assure the best safety and efficacy for the patient.
Physician, Nursing and CMCN credits valid to January 31, 2018
 
Improving Patient Outcomes in the Management of Hemophilia
The main treatment is replacement therapy; concentrates of clotting factor VIII are dripped or injected into a vein. This concentrated clotting factor can be made from human blood or not. Having regular treatments is referred to as prophylactic, or preventive therapy, and helps to prevent bleeding episodes. There is also demand therapy, where the replacement therapy is done on an as-need basis. While demand therapy is less expensive, there is a risk that the delay in treatment can cause damage to joints and muscles. Early treatment has been shown to have significant benefits to patient outcomes by preventing joint damage. Replacement therapy can be taught to a capable person, and infusions can be done at home, making for quicker treatment with less stress, less visits to the doctor, and less cost. However, it does require precise patient education and follow up. Another possibility for replacement therapy is having a vein access device implanted, which makes access easier. Antibodies are the biggest complication for replacement therapy. These antibodies, or inhibitors, develop in around 20% of people with hemophilia A. New and emerging treatments include longer lasting agents that will cut down on the number of infusions done per year, thus having the possibility of increasing patient compliance and possibly decreasing the possibility of inhibitors forming.
Physician, Nursing and CMCN credits valid to July 31, 2017
 
Psoriasis: Changing Approaches to the Treatment of Moderate to Severe Disease
There are several biologics, some newer than others, some administered in the doctor’s office, some by injection at home. Biologics require a reliable baseline of laboratory tests, regular blood testing, and patient education regarding the effect of biologics on their immune system and what vaccines they can have or must avoid. Biologics can be very effective in the treatment of psoriasis, but proper management must be done in order to assure the best safety and efficacy for the patient.
Physician, Nursing and CMCN credits valid to July 31, 2017
 
Disease Management Strategies for Moderate to Severe IBD in Adults
Treatment is based upon what type of IBD a patient has; there are medications that work better for Ulcerative Colitis (UC) than Crohns Disease (CD) and vice versa. Treatment includes anti-inflammatory drugs, along with immune system suppressors, which suppress the immune response that releases inflammation-inducing chemicals in the intestinal lining, and antibiotics may be given to help prevent or control infection. There are a few management strategies for treatment. The “step up” method involves prescribing milder drugs and escalating until the treatment goal is achieved. The “top down” method starts with an earlier introduction of biologics and immunomodulators. The top down method is believed to cut down complications and possibly achieve treatment goal more quickly than the step up method. The newest treatment management program is an individualized or personalized medicine-based plan. Believed to optimize efficacy of treatment and minimize complications, and thus decrease costs, personalized treatment uses algorithms, pre-testing, and monitoring, with defined targets to guide treatment intensification. Patient self-monitoring is an important part of individualized treatment, and the patient education and communication program needs to be vigilant. This type of treatment is still evolving with algorithms, validated scoring systems, and evidence-based guidelines being researched and studied. It is imperative that medical directors, practicing physicians, nurse case managers, and healthcare professionals involved in the treatment of IBD have the most up-to-date information available, in order to make appropriate patient care decisions.
Physician, Nursing and CMCN credits valid to July 31, 2017
 
AutoImmune    Cardiovascular     Diabetes     Infectious Disease     Musculoskeltal/Rheumatology     Neurological     Pain Management     Pulmonary
 

Cardiovascular
 

Updates in the Management of Pulmonary Arterial Hypertension (PAH)
Though relatively rare – affecting approximately six per one million people – PAH is a very serious, life threatening condition that worsens over time and for which there is no cure. Approximately half of people diagnosed with PAH will not live past five years, while those with untreated PAH have an average survival expectancy of approximately three years following diagnosis – and even with aggressive management, PAH has a 15% annual mortality rate. Associated treatment costs have risen with the expansion of treatment options, ranging from $18,000 to $244,000 annually per patient. Additionally, PAH often leads to the onset of co-morbidities associated with the disease, which not only puts the patient at higher risk but also increases the costs to the healthcare system. Early diagnosis and accurate classification are keys to managing costs, as incorrect classification can lead to inappropriate treatment decisions and unnecessary costs to the health care system. Emerging treatments including prostanoids are changing the way patients are being treated and clinicians need to understand how to apply treatment algorithms accordingly for pharmacologic decisions.

Physician, Nursing and CMCN credits valid to January 31, 2018
 

Optimal Anticoagulation Strategies for Stroke Prevention in Atrial Fibrillation
Atrial fibrillation (AF) is a common type of arrhythmia affecting both men and women, and the incidence increases with age. AF may be diagnosed based on tests, such as an EKG (electrocardiogram), ECG (echocardiography), stress test, blood tests, chests x-rays, a special monitor to record the heart’s rhythms, by physical exam, and medical and family histories. Preventing blood clots (thromboembolism), and thus strokes, may be the most important part of treating atrial fibrillation. The proven therapy is to prescribe anticoagulants, or blood thinners, to prevent blood clots. However studies have found that a significant number of patients in the US do not receive adequate therapy for stroke prevention and additionally, there are multiple concerns regarding blood thinners. Updates for emerging therapeutic agents for stroke prevention in AF patients will be reviewed along with newer anti-coagulants and management/treatment algorithms.
Physician, Nursing and CMCN credits valid to January 31, 2018
 
Updated Treatment Strategies in the Management of Obesity
Obesity has been shown to be a risk factor for a number of conditions, among them: coronary heart disease, type 2 diabetes, hypertension, stroke, and certain types of cancer. Fortunately, new pharmacologic agents have become available, giving physicians more management options, in addition to a reduced-calorie diet and exercise. Lifestyle changes are extremely important to treating obesity and should always be recommended in conjunction with the medication and require a lifetime behavioral modification which may be boosted with education, the use of support groups, counseling, and perhaps meeting with a dietitian. In light of the increasing prevalence of obesity in the United States, and the challenges in identifying treatment strategies for overweight and obese patients that will produce enduring weight loss, there is an urgent need for evidence-based education on these emerging treatments and strategies that physicians can apply to achieve clinically meaningful weight loss in individuals who meet medical criteria for pharmacologic intervention.
Physician, Nursing and CMCN credits valid to December 31, 2017
 
Advances in LDL-C Reduction: A Strategic Look at the Effectiveness of PCSK9 Inhibitors
Current guidelines agree that LDL-C is a major factor in the development of cardiovascular disease (CVD). In addition, it is well established that lowering LDL-C in high-risk patients reduces the risk for CVD. Primary prevention promotes lifestyle behaviors to prevent the development of accelerating risk factors as well as elevated LDL-C. Statins have typically been the first-line therapy and the choice of statins depends on availability, costs, and tolerability. In patients who are statin intolerant, several options are available and genetic insights into the study of LDL-C levels have expanded potential targets of drug therapy and led to the development of novel therapeutic agents. Among them are modulators containing lipoproteins production and proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors. Despite significant advances in the number of treatment options for advanced LDL-C management, there is a clear need for better education and the understanding of these new and emerging therapies that will improve outcomes.
Physician, Nursing and CMCN credits valid to December 31, 2017
 
Optimizing Outcomes in the Treatment of Lipid Management: Focusing on LDL-C Reduction
The discovery of statins has contributed a very effective approach to help battle the irregular levels of LDL-C. However, many patients do not achieve the recommended goals for LDL-C levels. Available agents combined with statins can provide additional LDL-C reduction, and agents in development will increase therapeutic options impacting other atherogenic lipoprotein classes. In fact, genetic insights into the study of LDL-C levels has expanded potential targets of drug therapy and led to the development of novel therapeutic agents. Among them are modulators containing lipoproteins production and proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors. These man-made antibodies block a protein that prevents the body from eliminating LDL cholesterol from the bloodstream and offer a new way of fighting the build-up of artery-clogging fatty deposits that put patients at risk of heart attacks. They work differently from widely-used statins - pills that inhibit the liver's production of LDL cholesterol in the first place, and to which some patients don't respond well. In earlier mid-stage studies, when combined with statins, alirocumab and the PCSK9 drug cut levels of LDL cholesterol by close to 70 percent, more than statins alone. Alternative targets such as lipoprotein also require attention; however, until there is a better understanding of these issues, further LDL-C lowering in high and very high-risk patients will represent the best clinical approach.
Physician, Nursing and CMCN credits valid to July 31, 2017
 

AutoImmune    Cardiovascular     Diabetes     Infectious Disease     Musculoskeltal/Rheumatology     Neurological     Pain Management     Pulmonary
 

Diabetes
 

A 4 Part Series:  New Horizons in the Treatment and Management of Type 2 Diabetes: Individualizing Therapy with Novel Options for Improved Patient Outcomes
Description:  The American Diabetes Association (ADA) estimates that more than 25.8 million people in the United States, or 8.3 percent of the population, have diabetes, and that one in three Americans born in 2016 will develop diabetes sometime during their lifetime. About 90-95% of adults who have diabetes have type 2 diabetes mellitus (DM). According to the Centers for Disease Control (CDC), uncontrolled type 2 DM doubles a person’s risk for death, and on average individuals with type 2 DM lose 10-15 years of life. The management of type 2 DM remains a major challenge as many patients continue to struggle with achieving therapeutic goals, including control of A1C level, blood pressure, cholesterol, and weight. Fortunately, recent advances in treatments in type 2 diabetes management have given healthcare professionals the ability to shrink this clinical practice gap.

Upon completion of these activities, it is anticipated that learners will be better able to identify the potential consequences of inadequate control of T2DM, apply objective disease-activity measures to determine whether patients are meeting treat-to-target goals, develop management plans for treating to target and advancing of novel therapies to achieve continued control of T2DM, and evaluate the role of the medical director, pharmacy director and nurse case manager in improving outcomes and costs in a population of T2DM patients.

Physician, Nursing and CMCN credits
apply.  Each session has its own specific valid dates
 

Exploring New Therapies in the Individualization of Treatment in Type 2 Diabetes Management: What Do They Have to Offer?
The American Diabetes Association (ADA) estimates that more than 25.8 million people in the United States, or 8.3 percent of the population, have diabetes, and that one in three Americans born in 2016 will develop diabetes sometime during their lifetime. About 90-95% of adults who have diabetes have type 2 diabetes mellitus (DM). According to the Centers for Disease Control (CDC), uncontrolled type 2 DM doubles a person’s risk for death, and on average individuals with type 2 DM lose 10-15 years of life. The management of type 2 DM remains a major challenge as many patients continue to struggle with achieving therapeutic goals, including control of A1C level, blood pressure, cholesterol, and weight. Fortunately, recent advances in treatments in type 2 diabetes management have given healthcare professionals the ability to shrink this clinical practice gap. This session, Part 1 of our series, will provide participants with the confidence and knowledge on new therapies in diabetes, patient identification for use of these therapies and the impact on clinical inertia.
Physician, Nursing and CMCN credits valid to March 30, 2019
 

Improving Glycemic Control and Cardiovascular Risk with Novel Therapies
The American Diabetes Association (ADA) estimates that more than 25.8 million people in the United States, or 8.3 percent of the population, have diabetes, and that one in three Americans born in 2016 will develop diabetes sometime during their lifetime. About 90-95% of adults who have diabetes have type 2 diabetes mellitus (DM). According to the Centers for Disease Control (CDC), uncontrolled type 2 DM doubles a person’s risk for death, and on average individuals with type 2 DM lose 10-15 years of life. The management of type 2 DM remains a major challenge as many patients continue to struggle with achieving therapeutic goals, including control of A1C level, blood pressure, cholesterol, and weight. Fortunately, recent advances in treatments in type 2 diabetes management have given healthcare professionals the ability to shrink this clinical practice gap. This session, Part 1 of our series, will provide participants with the confidence and knowledge on new therapies in diabetes, patient identification for use of these therapies and the impact on clinical inertia.
Physician, Nursing and CMCN credits valid to March 30, 2019
 

GLP-1 Agonists, Insulin and SGLT-2 Inhibitors in the Changing Treatment Paradigm: What are the Benefits, Risks and Outcomes in Patients with Type 2 Diabetes?
The American Diabetes Association (ADA) estimates that more than 25.8 million people in the United States, or 8.3 percent of the population, have diabetes, and that one in three Americans born in 2016 will develop diabetes sometime during their lifetime. About 90-95% of adults who have diabetes have type 2 diabetes mellitus (DM). According to the Centers for Disease Control (CDC), uncontrolled type 2 DM doubles a person’s risk for death, and on average individuals with type 2 DM lose 10-15 years of life. The management of type 2 DM remains a major challenge as many patients continue to struggle with achieving therapeutic goals, including control of A1C level, blood pressure, cholesterol, and weight. Fortunately, recent advances in treatments in type 2 diabetes management have given healthcare professionals the ability to shrink this clinical practice gap. This session, Part 1 of our series, will provide participants with the confidence and knowledge on new therapies in diabetes, patient identification for use of these therapies and the impact on clinical inertia.
Physician, Nursing and CMCN credits valid to March 30, 2019
 

What Managed Care Needs to Now About Novel Therapies in the Evolving Management of Type 2 Diabetes
The American Diabetes Association (ADA) estimates that more than 25.8 million people in the United States, or 8.3 percent of the population, have diabetes, and that one in three Americans born in 2016 will develop diabetes sometime during their lifetime. About 90-95% of adults who have diabetes have type 2 diabetes mellitus (DM). According to the Centers for Disease Control (CDC), uncontrolled type 2 DM doubles a person’s risk for death, and on average individuals with type 2 DM lose 10-15 years of life. The management of type 2 DM remains a major challenge as many patients continue to struggle with achieving therapeutic goals, including control of A1C level, blood pressure, cholesterol, and weight. Fortunately, recent advances in treatments in type 2 diabetes management have given healthcare professionals the ability to shrink this clinical practice gap. This session, Part 1 of our series, will provide participants with the confidence and knowledge on new therapies in diabetes, patient identification for use of these therapies and the impact on clinical inertia.

Physician, Nursing and CMCN credits valid to March 30, 2019
 

Improving Patient Outcomes with Individualized Therapy in the Management of Type 2 Diabetes
The management of type 2 DM remains a major challenge as many patients continue to struggle with achieving therapeutic goals, including control of A1C level, blood pressure, cholesterol, and weight. Fortunately, recent advances in treatments in Type 2 Diabetes management have given healthcare professionals the ability to shrink this clinical practice gap. Fortunately, recent advances in individualizing treatment through basal insulin therapy and GLP-1 analogs in Type 2 Diabetes management have given healthcare professionals the ability to shrink this clinical practice gap, particularly when they are combined. This session will review novel treatments and identify which patients are most likely to benefit from their use, which will help them achieve tighter glucose control and better clinical outcomes.
Physician, Nursing and CMCN credits valid to December 31, 2017
 
Updated Treatment Strategies in the Management of Obesity
Obesity has been shown to be a risk factor for a number of conditions, among them: coronary heart disease, type 2 diabetes, hypertension, stroke, and certain types of cancer. Fortunately, new pharmacologic agents have become available, giving physicians more management options, in addition to a reduced-calorie diet and exercise. Lifestyle changes are extremely important to treating obesity and should always be recommended in conjunction with the medication and require a lifetime behavioral modification which may be boosted with education, the use of support groups, counseling, and perhaps meeting with a dietitian. In light of the increasing prevalence of obesity in the United States, and the challenges in identifying treatment strategies for overweight and obese patients that will produce enduring weight loss, there is an urgent need for evidence-based education on these emerging treatments and strategies that physicians can apply to achieve clinically meaningful weight loss in individuals who meet medical criteria for pharmacologic intervention.
Physician, Nursing and CMCN credits valid to December 31, 2017
 
Effective A1c Reduction in Type 2 Diabetes: A Closer Look at Combination Insulin Therapy
According to the CDC, uncontrolled type 2 DM doubles a person’s risk for death, and on average individuals with type 2 DM lose 10-15 years of life. The management of type 2 DM remains a major challenge as many patients continue to struggle with achieving therapeutic goals, including control of A1C level, blood pressure, cholesterol, and weight. Fortunately, recent advances in individualizing treatment through basal insulin therapy and GLP-1 analogs in Type 2 Diabetes management have given healthcare professionals the ability to shrink this clinical practice gap, particularly when they are combined.
Physician, Nursing and CMCN credits valid to February 28, 2018
 
AutoImmune    Cardiovascular     Diabetes     Infectious Disease     Musculoskeltal/Rheumatology     Neurological     Pain Management     Pulmonary
 

Infectious Disease
 
AutoImmune    Cardiovascular     Diabetes     Infectious Disease     Musculoskeltal/Rheumatology     Neurological     Pain Management     Pulmonary
 
Improving Patient Outcomes with Individualized Therapy in the Management of HIV/AIDS
The human immunodeficiency virus (HIV) is a lentivirus that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS). AIDS is a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. Fortunately for patients with HIV, several new therapies have recently become available for clinicians. Antiretroviral therapy (ART) has evolved considerably over the past three decades with many antiretroviral (ARV) drugs, combinations, and classes available. Cobicistat-boosted protease inhibitors (PI) are also evolving and one of the biggest challenges for clinicians is individualizing care and understanding when certain ARV therapies and strategies are appropriate, and when they are not. Numerous studies have shown that ARV therapy must be tailored to the individual patient and his or her abilities and diverse needs. Options for HIV prevention and treatment continue to expand at a rapid pace.
Physician, Nursing and CMCN credits valid to December 31, 2018
 
Treatment of Chronic Hepatitis C Virus Infection
Hepatitis is the inflammation of the liver. There are several types of HCV, genotype 1A is the most prevalent in the US, and it’s been the most difficult to treat and cure. There are approximately 3.2 million people in the US with chronic Hepatitis C (CHC) infection. There could be many more, as HCV infections usually show mild to no symptoms. The most prevalent population believed to be infected with the hepatitis C virus (HCV) were born from 1945 to 1965 and probably infected during the 1970’s and ‘80’s, and many of them still are undiagnosed due to the lack of symptoms. Fortunately for patients with hepatitis C, several new treatment options have become available, giving physicians individualized options with vastly increased cure rates.

This program on overcoming challenges in HCV management with novel therapies will take a close look at genotype 1 and 4 HCV, providing attendees with education that will assist them in developing the best strategy to improve outcomes for their Hepatitis C member population. Attendees will leave with ability to increase screening protocols for Hepatitis C, and understand treatment barriers and solutions for patient adherence, as well as the ability to help educate both their staff and colleagues, which will ultimately increase organizational quality and, most importantly, improve outcomes and quality of life in patients.

Physician, Nursing and CMCN credits valid to December 31, 2018
 
Advances in the Management of Hepatitis C: A Closer Look at Emerging Treatment Options
There are approximately 3.2 million people in the US with chronic Hepatitis C (CHC) infection. There could be many more, as HCV infections usually show mild to no symptoms. The most prevalent population believed to be infected with the hepatitis C virus (HCV) were born from 1945 to 1965 and probably infected during the 1970’s and ‘80’s, and many of them still are undiagnosed due to the lack of symptoms. Fortunately for patients with hepatitis C, several new treatment options have become available, giving physicians individualized options with vastly increased cure rates. There are several Types of HCV, genotype 1A is the most prevalent in the US, and it’s been the most difficult to treat and cure. Screening has been recommended by the Centers for Disease Control and Preventions (CDC), since diagnosing and treating HCV before severe liver damage or cirrhosis has occurred, greatly decreases the chance of liver cancer or death.

Treatment can be a complicated issue due to harsh side effects ranging from fatigue, vision problems, depression or anxiousness, skin rash and fast heartbeat or chest pain, which cause a large problem for patient adherence. Fortunately for patients with HCV, newer treatments have become available, with a much shorter treatment time, increased efficacy and fewer side effects. Direct acting antiviral agents (DAA’s) are oral drugs that have fewer major side effects. When combined with traditional or new therapies, the cure rate increases tremendously and the treatment time required is greatly decreased, thus making patient compliance much easier to maintain and improving patient outcomes.
Physician, Nursing and CMCN credits valid to July 31, 2017
 
Best Practices in the Management of Hepatitis C: Individualizing Therapy with Emerging Options
There are approximately 3.2 million people in the US with chronic Hepatitis C (CHC) infection. There could be many more, as HCV infections usually show mild to no symptoms. The most prevalent population believed to be infected with the hepatitis C virus (HCV) were born from 1945 to 1965 and probably infected during the 1970’s and ‘80’s, and many of them still are undiagnosed due to the lack of symptoms. Fortunately for patients with hepatitis C, several new treatment options have become available, giving physicians individualized options with vastly increased cure rates. There are several Types of HCV, genotype 1A is the most prevalent in the US, and it’s been the most difficult to treat and cure. Screening has been recommended by the Centers for Disease Control and Preventions (CDC), since diagnosing and treating HCV before severe liver damage or cirrhosis has occurred, greatly decreases the chance of liver cancer or death.

Treatment can be a complicated issue due to harsh side effects ranging from fatigue, vision problems, depression or anxiousness, skin rash and fast heartbeat or chest pain, which cause a large problem for patient adherence. Fortunately for patients with HCV, newer treatments have become available, with a much shorter treatment time, increased efficacy and fewer side effects. Direct acting antiviral agents (DAA’s) are oral drugs that have fewer major side effects. When combined with traditional or new therapies, the cure rate increases tremendously and the treatment time required is greatly decreased, thus making patient compliance much easier to maintain and improving patient outcomes.
Physician, Nursing and CMCN credits valid to February 28, 2017
 
AutoImmune    Cardiovascular     Diabetes     Infectious Disease     Musculoskeltal/Rheumatology     Neurological     Pain Management     Pulmonary
 

Musculoskeletal & Rheumatology
 

A 4 Part Series:  New Horizons in the Treatment and Management of Rheumatoid Arthritis
Description:
  Rheumatoid arthritis (RA) is a long-lasting autoimmune disorder that occurs when the immune system mistakenly attacks the body's own tissues. It typically results in warm, swollen, and painful joints, and pain and stiffness often worsen following rest. Most commonly, the wrist and hands are involved, with the same joints typically involved on both sides of the body. According to the American College of Rheumatology (ACR), it is estimated that over 1.3 million people suffer from RA in the United States. The disease may also affect other parts of the body, which results in a low red blood cell count, inflammation around the lungs, and inflammation around the heart. Fortunately for patients with RA, a new class of treatments called janus kinase (JAK) inhibitors have become available recently. Some have been approved for use and some showing improved safety and efficacy have just completed late stage clinical trials and are awaiting regulatory review. With so many new options becoming available for clinicians, it is critical that rheumatologists, primary care physicians, managed care medical directors, payers, case managers, nurses, and other healthcare professionals (HCPs) are updated on these emerging options and guidelines and strategies for implementing them into the treatment paradigm, which will ultimately improve patient outcomes.
Physician, Nursing and CMCN credits
apply.  Each session has its own specific valid dates
 

Exploring Mechanisms of Action in JAK Inhibitors and the Role of the JAK/STAT Pathway in the Pathogenesis of RA
Rheumatoid arthritis (RA) is a long-lasting autoimmune disorder that occurs when the immune system mistakenly attacks the body's own tissues. Per the American College of Rheumatology (ACR), it is estimated that over 1.3 million people suffer from RA in the United States. Fortunately for patients with RA, a new class of treatments called janus kinase (JAK) inhibitors have become available recently. Some have been approved for use and some showing improved safety and efficacy have just completed late stage clinical trials and are awaiting regulatory review. Significant developments have taken place in the treatment paradigm with the emergence of JAK inhibitors in the past few years, which has created knowledge gaps for translating these developments into managed care and clinical decision making. This session will provide the mechanism of action, the role and differences of JAK inhibitors.
Physician, Nursing and CMCN credits valid to April 30, 2019
 

Where Do JAK inhibitors Fit in the Emerging Treatment Paradigm in the Management of RA
Rheumatoid arthritis (RA) is a long-lasting autoimmune disorder that occurs when the immune system mistakenly attacks the body's own tissues. Per the American College of Rheumatology (ACR), it is estimated that over 1.3 million people suffer from RA in the United States. Fortunately for patients with RA, a new class of treatments called janus kinase (JAK) inhibitors have become available recently. Some have been approved for use and some showing improved safety and efficacy have just completed late stage clinical trials and are awaiting regulatory review. Significant developments have taken place in the treatment paradigm with the emergence of JAK inhibitors in the past few years, which has created knowledge gaps for translating these developments into managed care and clinical decision making. This session will provide the mechanism of action, the role and differences of JAK inhibitors.

Physician, Nursing and CMCN credits valid to April 30, 2019
 

How to Improve Patient Adherence and Safety in RA: Strategies to Monitor and Manage Adverse Events Associated with Emerging JAK Inhibitors
Rheumatoid arthritis (RA) is a long-lasting autoimmune disorder that occurs when the immune system mistakenly attacks the body's own tissues. Per the American College of Rheumatology (ACR), it is estimated that over 1.3 million people suffer from RA in the United States. Fortunately for patients with RA, a new class of treatments called janus kinase (JAK) inhibitors have become available recently. Some have been approved for use and some showing improved safety and efficacy have just completed late stage clinical trials and are awaiting regulatory review. Significant developments have taken place in the treatment paradigm with the emergence of JAK inhibitors in the past few years, which has created knowledge gaps for translating these developments into managed care and clinical decision making. This session will provide the mechanism of action, the role and differences of JAK inhibitors.
Physician, Nursing and CMCN credits valid to April 30, 2019
 
What Managed Care Needs to Know About JAK Inhibitors in the Evolving Management of RA
Rheumatoid arthritis (RA) is a long-lasting autoimmune disorder that occurs when the immune system mistakenly attacks the body's own tissues. Per the American College of Rheumatology (ACR), it is estimated that over 1.3 million people suffer from RA in the United States. Fortunately for patients with RA, a new class of treatments called janus kinase (JAK) inhibitors have become available recently. Some have been approved for use and some showing improved safety and efficacy have just completed late stage clinical trials and are awaiting regulatory review. Significant developments have taken place in the treatment paradigm with the emergence of JAK inhibitors in the past few years, which has created knowledge gaps for translating these developments into managed care and clinical decision making. This session will provide the mechanism of action, the role and differences of JAK inhibitors.
Physician, Nursing and CMCN credits valid to April 30, 2019
 
Recent Advances in the Management of Rheumatoid Arthritis: A Closer Look at Emerging Therapies
Rheumatoid arthritis (RA) is a long-lasting autoimmune disorder that occurs when the immune system mistakenly attacks the body's own tissues which typically result in warm, swollen, and painful joints. Additionally, systemic complications and comorbid conditions make the disease difficult to manage. There is no cure for RA thus treatment focuses on managing the disease and controlling symptoms. Fortunately, several new medications have become available as many patients have an inadequate response or can become intolerant to the widely used anti-TNF therapies. Clinicians have recently been equipped with more treatment options, including janus kinase (JAK) inhibitors which are changing the way RA patients are treated.
Physician, Nursing and CMCN credits valid to January 31, 2018
 
AutoImmune    Cardiovascular     Diabetes     Infectious Disease     Musculoskeltal/Rheumatology     Neurological     Pain Management     Pulmonary
 
Neurological
 
7 Part Series - New Horizons in the Treatment and Management of Multiple Sclerosis: Best Practices for Improved Patient Outcomes
New Horizons in the Treatment and Management of Multiple Sclerosis is a 7-part series that will provide participants with the latest information in MS management. By clicking on each of the titles, you will be able to participate in each part. It is not required that you participate in all 7 or in order. These are archives of live webinars held between December 7, 2016 and February 1, 2017.
Physician, Nursing and CMCN credits
 
Managing Relapse in MS – Strategies for Switching Therapy after Inadequate Response to Previous Treatment Regimens
Effective and timely treatment of relapsing MS can greatly improve the quality of life in MS patients. With the advancement and complexity of different treatment options, including therapies that have recently become available, clinicians are being challenged to quickly diagnose MS and its corresponding symptoms, and provide the correct treatment options that are available to patients. As part of a multi-part webinar program this session will focus on managing relapse and switching therapy. It is critical that HCPs who will be in attendance for the live webinar, or participate in any of the enduring materials, learn about these emerging agents and how to incorporate them into their respective management strategies.
Physician, Nursing and CMCN credits valid to January 31, 2019
 

Oral Therapies, Autoinjectors and Dosing/Administration in the Changing MS Management Paradigm: Overcoming Barriers to Treatment
Although there is still no cure for MS, many advances in MS treatment have arrived in recent years, allowing patients to manage these symptoms and improve their quality of life. Lack of early implementation of appropriate interventions based on a balance of efficacy and safety of current and emerging therapies, updated guidelines and the newest clinical data leads to inadequate control of MS. This session will provide attendees with an updated review of therapies, dosing methods, overcoming potential barriers and how these affect patient adherence.
Physician, Nursing and CMCN credits valid to March 31, 2018

 

What’s on the Horizon in MS: A Review of Novel Therapies and Emerging Approaches
Although there is still no cure for MS, many advances in MS treatment have arrived in recent years, allowing patients to manage these symptoms and improve their quality of life. Lack of early implementation of appropriate interventions based on a balance of efficacy and safety of current and emerging therapies, updated guidelines and the newest clinical data leads to inadequate control of MS. This session will provide attendees with an updated review of therapies, dosing methods, overcoming potential barriers and how these affect patient adherence.
Physician, Nursing and CMCN credits valid to March 31, 2018
 
Insights on the Interplay of B cells and T cells in Therapeutic MS Management
Although there is still no cure for MS, many advances in MS treatment have arrived in recent years, allowing patients to manage these symptoms and improve their quality of life. Lack of early implementation of appropriate interventions based on a balance of efficacy and safety of current and emerging therapies, updated guidelines and the newest clinical data leads to inadequate control of MS. This session will provide attendees with an updated review of therapies, dosing methods, overcoming potential barriers and how these affect patient adherence.
Physician, Nursing and CMCN credits valid to March 31, 2019
What’s on the Horizon in MS: What Managed Care Needs to Know in the Evolving Management of MS
Although there is still no cure for MS, many advances in MS treatment have arrived in recent years, allowing patients to manage these symptoms and improve their quality of life. Lack of early implementation of appropriate interventions based on a balance of efficacy and safety of current and emerging therapies, updated guidelines and the newest clinical data leads to inadequate control of MS. This session will provide attendees with an updated review of therapies, dosing methods, overcoming potential barriers and how these affect patient adherence.
Physician, Nursing and CMCN credits valid to March 31, 2018
 
New Horizons in the Treatment and Management of Multiple Sclerosis: The Role of Vitamin D in Multiple Sclerosis Pathology and Treatment
Although there is still no cure for MS, many advances in MS treatment have arrived in recent years, allowing patients to manage these symptoms and improve their quality of life. Lack of early implementation of appropriate interventions based on a balance of efficacy and safety of current and emerging therapies, updated guidelines and the newest clinical data leads to inadequate control of MS. This session will provide attendees with an updated review of therapies, dosing methods, overcoming potential barriers and how these affect patient adherence. This session will provide attendees with the role and impact of vitamin D on clinical outcomes and neuroprotective mechanisms in MS.
Physician, Nursing and CMCN credits valid to March 31, 2018
 
Evaluation and Management of Overactive Bladder
Overactive bladder (OAB) is a highly prevalent condition that occurs about twice as frequently in women as in men, and while OAB is not considered a normal part of aging, it does become more prevalent with advanced age. OAB has a significant impact on quality of life (QoL), co-morbidities and cost; sufferers are two to three times more likely to experience disturbed sleep, overeating, poor self-esteem, and depression. Despite its impact, OAB remains underdiagnosed and undertreated thus screening and evaluating patients is of utmost importance in order to improve diagnosis and patient QoL. Fortunately there are a variety of treatments available from behavioral modification (drink less fluid, caffeine…etc.) to antimuscarinic agents and ß3-adrenoceptor agonists. There is a stepwise progression in the management of OAB and multiple options of treatment available in each of the lines of therapy provide for a tailored approach to individualize treatment based upon a patient’s expectation and goal for treatment, their co-morbidities, symptoms, and the side-effects of treatments.
Physician, Nursing and CMCN credits valid to December 31, 2017
 
Seizure & Epilepsy Care
Epilepsy is a chronic neurological disorder where the nerve cell activity in the brain becomes disrupted, causing seizures or periods of unusual behavior. Epilepsy affects about 3 million people in the United States and accounts for about $15 billion in medical costs. Some drugs are more effective for specific types of seizures and the goal for neurologists is to achieve a seizure-free status for their patients without adverse effects. Treatment of epilepsy involves reducing the number of seizures by administering various antiepileptic drugs (AEDs) and about 60% of patients require treatment with anticonvulsants. Unfortunately, more than one-third of people who experience seizures continue to have issues despite the medication given. Many patients do not have all the treatments available to them because their seizures are not adequately controlled, or because they experience severe adverse effects. The development of new AEDs continues to increase and drug therapies can now be individualized to the patient’s symptoms and needs. It is also important to understand the mechanisms of action and the pharmacokinetics of antiepileptic drugs so that these agents can be used effectively in clinical practice, especially in the combined therapeutic strategies.
Physician, Nursing and CMCN credits valid to December 31, 2017
 
New Horizons in the Treatment and Management of Multiple Sclerosis: Exploring Novel Mechanisms of Action in the Treatment of MS
Effective and timely treatment of relapsing MS can greatly improve the quality of life in MS patients. With the advancement and complexity of different treatment options, including therapies that have recently become available, clinicians are being challenged to quickly diagnose MS and its corresponding symptoms, and provide the correct treatment options that are available to patients. As part of a multi-part webinar program this session will focus on novel mechanisms of action. It is critical that HCPs who will be in attendance for the live webinar, or participate in any of the enduring materials, learn about these emerging agents and how to incorporate them into their respective management strategies.
Physician, Nursing and CMCN credits valid to December 31, 2018
 
Evolving Treatment Options and Strategies in Multiple Sclerosis
Multiple Sclerosis (MS) is a chronic progressive disease and is the most common neurological cause of disability among young adults, with a prevalence of approximately 400,000 cases throughout the United States. Although there is still no cure for MS, many advances in MS treatment have arrived in recent years, allowing patients to manage these symptoms and improve their quality of life. A number of factors must be considered when selecting a treatment regimen for patients with MS, including variations in clinical and MRI evidence of disease. Over the past decade, there have been numerous revisions to MS diagnostic criteria and the development of multiple new and emerging therapies. While the explosion of these emerging therapies have shown the ability to improve outcomes and quality of life in patient's relapsing MS, it makes staying current with best practices a challenge that must be overcome through education. These new options must be compared and contrasted with current treatments, including immunomodulatory agents, to ultimately form an individualized treatment strategy for each MS patient.
Physician, Nursing and CMCN credits valid to December 31, 2017
 
Improving Parkinson's Disease Symptoms and Psychosis
There is no one test to confirm diagnosis of Parkinson’s disease. Diagnosis is done through medical exam, review of symptoms, and a series of tests to rule out other possible causes, blood tests, PET scan, CT scan and MRI may be used. Currently there is no cure for Parkinson’s disease. Symptoms are caused by a loss of neurons in the brain that produce the chemical messenger called dopamine. These neurons break down or die and will no longer create dopamine. As the dopamine levels in the brain decrease, the symptoms of PD increase. Scientists have not yet been able to figure out the trigger or what is causing the neurons to breakdown. Thus treatment focuses mainly on treating the symptoms and improving the quality of life.

While the greatest focus for treating Parkinson’s disease (PD) is the four primary motor symptoms of tremor, rigidity, bradykinesia (slowness of movement), and impaired balance and coordination, there are non-motor symptoms of PD, including depression, apathy, dementia, and psychosis that can be debilitating to the patient’s quality of life, and must be screened for and treated upon diagnosis. Dopaminergic therapies are known to cause some neuropsychiatric issues and sometimes adjustment of the therapy will relieve the symptoms. However, sometimes an antipsychotic medication will be necessary. The management plan for PDS will need to be balanced with the management of the treatment for motor symptoms. Treatment of PDS can improve patient outcomes and quality of life as well as reduce the over-all cost of lifetime treatment.

Physician, Nursing and CMCN credits valid to July 31, 2017
 
Best Practices in the Treatment and Management of Multiple Sclerosis
Although there is still no cure for MS, many advances in MS treatment have arrived in recent years, allowing patients to manage these symptoms and improve their quality of life. A number of factors must be considered when selecting a treatment regimen for patients with MS, including variations in clinical and MRI evidence of disease. Over the past decade, there have been numerous revisions to MS diagnostic criteria and the development of multiple new and emerging therapies. With the advancement and complexity of different treatment options, including therapies that have recently become available, clinicians are being challenged to quickly diagnose MS and its corresponding symptoms, and provide the correct treatment options that are available to patients. Recent surveys and research have shown that clinicians need updates on these new emerging options, and how they can integrate them into the treatment paradigm.
Physician, Nursing and CMCN credits valid to July 31, 2017
 
Updated Diagnostic and Individualized Treatment Strategies in the Management of Overactive Bladder (OAB)
Despite its impact, OAB remains underdiagnosed and undertreated. Screening and evaluating patients is of utmost importance in order to improve diagnosis and patient quality of life. Guidelines established by the American Urologic Association (AUA) include a stepwise progression in the management of OAB. Multiple options of treatment are available in each of the lines of therapy to provide for a tailored approach to individualize treatment based upon a patient’s expectation and goal for treatment, their co-morbidities, symptoms, and the side-effects of treatments. There is a stepwise progression in the management of OAB and multiple options of treatment available in each of the lines of therapy provide for a tailored approach to individualize treatment based upon a patients expectation and goal for treatment, their co-morbidities, symptoms, and the side-effects of treatments, what works and does not work will vary patient to patient, and it’s important to keep communications open to determine if a patient is unable to remain compliant to treatment due to side-effects or cost.
Physician, Nursing and CMCN credits valid to July 31, 2017
 
Clinical Advances & Therapeutic Strategies for Patients with Epilepsy
Epilepsy affects about 3 million people in the United States and accounts for about $15 billion in medical costs. For about 70 percent of those diagnosed with epilepsy, seizures can be controlled with medications and different surgical techniques. Some drugs are more effective for specific types of seizures. Patients who experience seizures, particularly those that are not easily controlled, need to seek out neurological guidance. The goal for neurologists is to achieve a seizure-free status for their patients without adverse effects and about 60% of patients require treatment with anticonvulsants.
Physician, Nursing and CMCN credits valid to July 31, 2017
 
AutoImmune    Cardiovascular     Diabetes     Infectious Disease     Musculoskeltal/Rheumatology     Neurological     Pain Management     Pulmonary
 

Pain Management
 
Management Strategies of Chronic Pain; Let’s Talk about Opioids
Chronic pain is defined as pain that has lasted for over three months, is persistent and causes a loss of quality of life, often due to depression, loss of job productivity, and loss of socialization. It may have started out as acute pain, caused by some injury or other problem and the most common types of chronic pain are associated with back pain, headaches, arthritis, nerves, muscles, and pain caused by cancer. Close to half of patients with chronic pain are left untreated and even with those untreated the economic cost is staggering with an estimated $100 billion in lost income, lost productivity, and increased healthcare expenses. It’s important the chronic pain treatment include several types such as pharmaceutical, physical, and lifestyle changes. This multi-dimensional approach has a higher probability for pain relief or management, and the potential to avoid addiction and dependence to pain relievers. Options include over the counter (OTC) pain relievers, prescription NSAIDs, or opioids, physical therapy, diet, exercise, massage, and possibly meditation and acupuncture. Currently, the FDA has put out the REMS program for ER/LA opioids because these types of pain medicines have clearly emerged as those with the highest potential for harm from misuse, abuse, and unintentional overdose. When all other forms of pain medication and treatment have been ineffective at controlling the pain, opioid analgesics may be required, if so therapy management will need to be strictly implemented in order to prevent addiction, abuse or other adverse effects.
Physician, Nursing and CMCN credits valid to December 31, 2017
 
Opioid Induced Constipation: The Side Effect that Adversely Affects Patient Adherence
In 2013, the National Institute of Health reported that there were approximately 200 million prescriptions dispensed for opioid pain medication. This trend has grown more than 50% in the last 10 years. Almost all patients requiring chronic opioid therapy develop side effects, and the most common side effect is to the gastrointestinal resulting in opioid induced constipation (OIC). Numbers vary regarding prevalence of OIC, and has been reported to be somewhere between 40-95% of patients develop OIC, with the highest prevalence in patients with severe acute and chronic non-cancer pain.
Physician, Nursing and CMCN credits valid to July 31, 2017
 
 
AutoImmune    Cardiovascular     Diabetes     Infectious Disease     Musculoskeltal/Rheumatology     Neurological     Pain Management     Pulmonary
 

Pulmonary
 

Updates in the Management of Pulmonary Arterial Hypertension (PAH)
Though relatively rare – affecting approximately six per one million people – PAH is a very serious, life threatening condition that worsens over time and for which there is no cure. Approximately half of people diagnosed with PAH will not live past five years, while those with untreated PAH have an average survival expectancy of approximately three years following diagnosis – and even with aggressive management, PAH has a 15% annual mortality rate. Associated treatment costs have risen with the expansion of treatment options, ranging from $18,000 to $244,000 annually per patient. Additionally, PAH often leads to the onset of co-morbidities associated with the disease, which not only puts the patient at higher risk but also increases the costs to the healthcare system. Early diagnosis and accurate classification are keys to managing costs, as incorrect classification can lead to inappropriate treatment decisions and unnecessary costs to the health care system. Emerging treatments including prostanoids are changing the way patients are being treated and clinicians need to understand how to apply treatment algorithms accordingly for pharmacologic decisions.

Physician, Nursing and CMCN credits valid to January 31, 2018
 

Advances in the Management of Cystic Fibrosis: A Closer Look at the Roles of CFTR Modulation Therapy
According to the Cystic Fibrosis (CF) Foundation, about 30,000 people are currently living with cystic fibrosis, and approximately 1,000 new cases of CF are diagnosed each year. There is no cure for cystic fibrosis, but recent treatment breakthroughs have the ability to provide a greater quality of life and improved outcomes for patients with CF. CF is an autosomal recessive disorder, caused by the presence of mutations in both copies of the gene for the protein cystic fibrosis transmembrane conductance regulator (CFTR). Fortunately for about half of CF patients, a new treatment is available for those who have two copies of the F508del mutation in their CFTR gene. This new CFTR modulation therapeutic focuses on counteracting the damage caused by the disease, enabling patients to breathe more easily and stay out of the hospital, improving outcomes and quality of life. This option is a major breakthrough in CF management, because it is the first therapy that specifically targets an important genetic mutation.
Physician, Nursing and CMCN credits valid to January 31, 2018
 
Strategies for Updated Treatment Options for IPF
Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias, and is a devastating disease associated with irreversible destruction of the lung. There are more than 80,000 adults in the US that have IPF and more than 30,000 cases are diagnosed each year, being more common in men than in women. IPF typically has a poor prognosis with a median survival of 3 years, thus it is imperative that clinicians diagnosis the disease early in order to implement appropriate management options to control symptoms and slowing of the disease progression to best maintain patient quality of life. Although there is no cure for IPF, there are numerous treatment options that have become available in the past several years. These options include corticosteroids, proton pump inhibitors, antioxidants and immune suppressants. There have also been advances in the pharmacological management which include nintedanib and pirfenidone. These effective therapies have shown improvement in a patient’s quality of life by slowing the progression of the lung tissue damage. Recent clinical trials have identified new treatments for this disease which lead to the approval of new therapeutic options by the FDA. The education of healthcare professionals will help with the appropriate use of current and newly approved medications as well as giving effective management strategies.
Physician, Nursing and CMCN credits valid to December 31, 2017
 
Key Advances in the Treatment and Management of Asthma
As progress is made in the scientific understanding of airway inflammation and narrowing, the prevalence of asthma continues to rise, and there is a clear need for improved diagnosis and more aggressive and effective treatment. Consequently, many studies show insufficient patient adherence to prescribed and behavioral treatment regimens, leading to a major cause of poor clinical outcomes. Patients with asthma often do not have their asthma well controlled due to many different barriers including: age, socioeconomic status, complexity of the treatment plan and lack of education. For improved asthma management, these factors must be addressed and solutions sought, so that adherence can be more accurately targeted and treated through increased assessment.

While there is no cure for asthma, it is possible to manage the disease successfully through a number of behavioral changes and therapies, such as decreasing exposure to allergens and by using an inhaled corticosteroids (ICS) and/or long-acting beta-2 agonists. There are also several new therapies emerging in clinical trials which aim to help control and treat asthma. These treatments have shown to improve lung function and decrease rescue bronchodilator use. The treatment goals for most asthmatic patients are to reduce the frequency and intensity of symptoms and reduce the risk of future asthma attacks, as these attacks lead to the decline in lung function.
Physician, Nursing and CMCN credits valid to December 31, 2017
 
Identifying New Strategies to Optimize the Management & Treatment of COPD
The recently updated guidelines, Global Initiative for Chronic Obstructive Lung Disease (GOLD), recommend that all COPD patients should continuously be assessed based on their symptoms, the severity of airflow limitation, frequency of exacerbations, and comorbidities. A major advance in COPD management is the recognition that COPD exacerbations can be prevented, and that individuals at risk for first or recurrent exacerbations can be identified sooner than later. The updated guidelines recommend all healthcare professionals who treat COPD patients choose an appropriate treatment regimen made up of both pharmacologic and non-pharmacologic therapies based on individual assessment results. Although most healthcare professionals believe that proper therapeutic treatment can slow progression, without proper knowledge or adherence to new global practice guidelines, awareness of appropriate and safe therapies, and improved implementation knowledge, the current and future burden of COPD will likely increase.
Physician, Nursing and CMCN credits valid to July 31, 2017
 
Optimizing Treatment Strategies to Improve Outcomes in the Management of Cystic Fibrosis
According to the Cystic Fibrosis (CF) Foundation, about 30,000 people are currently living with cystic fibrosis, and approximately 1,000 new cases of CF are diagnosed each year. There is no cure for cystic fibrosis, but recent treatment breakthroughs have the ability to provide a greater quality of life and improved outcomes for patients with CF. CF is an autosomal recessive disorder, caused by the presence of mutations in both copies of the gene for the protein cystic fibrosis transmembrane conductance regulator (CFTR). Fortunately for about half of CF patients, a new treatment is available for those who have two copies of the F508del mutation in their CFTR gene. This new CFTR modulation therapeutic focuses on counteracting the damage caused by the disease, enabling patients to breathe more easily and stay out of the hospital, improving outcomes and quality of life. This option is a major breakthrough in CF management, because it is the first therapy that specifically targets an important genetic mutation.
Physician, Nursing and CMCN credits valid to July 31, 2017
 
Pulmonary Arterial Hypertension: Towards a Brighter Future for Patients
Though relatively rare – affecting approximately six per one million people – PAH is a very serious, life threatening condition that worsens over time and for which there is no cure. Approximately half of people diagnosed with PAH will not live past five years, while those with untreated PAH have an average survival expectancy of approximately three years following diagnosis – and even with aggressive management, PAH has a 15% annual mortality rate. Associated treatment costs have risen with the expansion of treatment options, ranging from $18,000 to $244,000 annually per patient. Additionally, PAH often leads to the onset of co-morbidities associated with the disease, which not only puts the patient at higher risk but also increases the costs to the healthcare system. Early diagnosis and accurate classification are keys to managing costs, as incorrect classification can lead to inappropriate treatment decisions and unnecessary costs to the health care system.
Physician, Nursing and CMCN credits valid to July 31, 2017
 
Improving Outcomes in the Management & Treatment of Asthma
Even as progress is made in the scientific understanding of airway inflammation and narrowing, the prevalence of asthma continues to rise, and there is a clear need for improved diagnosis and more aggressive and effective treatment. Consequently, there are many studies that show insufficient patient adherence to prescribed and behavioral treatment regimens is a major cause of poor clinical outcomes. Due to many different barriers, patients with asthma often do not have their asthma well controlled, leading to poor patient outcomes. Greater attention is needed for the management of asthma to help patients achieve asthma adherence and control. With better control, patients with asthma will experience less suffering from asthma symptoms, which will ultimately lead to fewer missed days at school and at work, less emergency department visits, and hospitalizations, and ultimately prolonged life. While there is no cure for asthma, it is possible to manage the disease successfully through a number of behavioral changes and therapies.
Physician, Nursing and CMCN credits valid to July 31, 2017
 

AutoImmune    Cardiovascular     Diabetes     Infectious Disease     Musculoskeltal/Rheumatology     Neurological     Pain Management     Pulmonary